169 related articles for article (PubMed ID: 25460570)
1. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model.
Orozco JJ; Balkin ER; Gooley TA; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Hylarides MD; Shadman M; Green DJ; Gopal AK; Press OW; Pagel JM
PLoS One; 2014; 9(12):e113601. PubMed ID: 25460570
[TBL] [Abstract][Full Text] [Related]
2. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
Orozco JJ; Bäck T; Kenoyer A; Balkin ER; Hamlin DK; Wilbur DS; Fisher DR; Frayo SL; Hylarides MD; Green DJ; Gopal AK; Press OW; Pagel JM
Blood; 2013 May; 121(18):3759-67. PubMed ID: 23471305
[TBL] [Abstract][Full Text] [Related]
4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
5. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.
Orozco JJ; Kenoyer A; Balkin ER; Gooley TA; Hamlin DK; Wilbur DS; Hylarides MD; Frost SH; Mawad R; O'Donnell P; Sandmaier BM; Fuchs EJ; Luznik L; Green DJ; Gopal AK; Press OW; Pagel JM
Blood; 2016 Jan; 127(3):352-9. PubMed ID: 26576864
[TBL] [Abstract][Full Text] [Related]
8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
Pagel JM; Kenoyer AL; Bäck T; Hamlin DK; Wilbur DS; Fisher DR; Park SI; Frayo S; Axtman A; Orgun N; Orozco J; Shenoi J; Lin Y; Gopal AK; Green DJ; Appelbaum FR; Press OW
Blood; 2011 Jul; 118(3):703-11. PubMed ID: 21613259
[TBL] [Abstract][Full Text] [Related]
11. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
Nakamae H; Wilbur DS; Hamlin DK; Thakar MS; Santos EB; Fisher DR; Kenoyer AL; Pagel JM; Press OW; Storb R; Sandmaier BM
Cancer Res; 2009 Mar; 69(6):2408-15. PubMed ID: 19244101
[TBL] [Abstract][Full Text] [Related]
12. Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.
O'Donnell RT; DeNardo SJ; Miers LA; Kukis DL; Mirick GR; Kroger LA; DeNardo GL
Cancer Biother Radiopharm; 1998 Oct; 13(5):351-61. PubMed ID: 10851425
[TBL] [Abstract][Full Text] [Related]
13. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
14. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
[TBL] [Abstract][Full Text] [Related]
15. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Efficacy of Radioimmunotherapy with 90Y-Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models.
Sugyo A; Tsuji AB; Sudo H; Okada M; Koizumi M; Satoh H; Kurosawa G; Kurosawa Y; Saga T
PLoS One; 2015; 10(4):e0123761. PubMed ID: 25893775
[TBL] [Abstract][Full Text] [Related]
17. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts.
Ning S; Trisler K; Wessels BW; Knox SJ
Cancer; 1997 Dec; 80(12 Suppl):2519-28. PubMed ID: 9406705
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates.
Schott ME; Schlom J; Siler K; Milenic DE; Eggensperger D; Colcher D; Cheng R; Kruper WJ; Fordyce W; Goeckeler W
Cancer; 1994 Feb; 73(3 Suppl):993-8. PubMed ID: 8306291
[TBL] [Abstract][Full Text] [Related]
19. Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
Pagel JM; Hedin N; Drouet L; Wood BL; Pantelias A; Lin Y; Hamlin DK; Wilbur DS; Gopal AK; Green D; Appelbaum FR; Press OW
Blood; 2008 Feb; 111(4):2261-8. PubMed ID: 18042793
[TBL] [Abstract][Full Text] [Related]
20. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]